These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237 [TBL] [Abstract][Full Text] [Related]
4. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas. Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769 [TBL] [Abstract][Full Text] [Related]
5. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study. Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508 [TBL] [Abstract][Full Text] [Related]
6. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905 [TBL] [Abstract][Full Text] [Related]
7. The detection of quantitative serum p53 protein in lung cancer. Sen E; Gönüllü U; Akar N Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881 [TBL] [Abstract][Full Text] [Related]
8. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers. Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411 [TBL] [Abstract][Full Text] [Related]
9. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916 [TBL] [Abstract][Full Text] [Related]
10. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133 [TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569 [TBL] [Abstract][Full Text] [Related]
12. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945 [TBL] [Abstract][Full Text] [Related]
13. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451 [TBL] [Abstract][Full Text] [Related]
14. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies. Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330 [TBL] [Abstract][Full Text] [Related]
15. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Kaur J; Srivastava A; Ralhan R Int J Cancer; 1997 Dec; 74(6):609-13. PubMed ID: 9421357 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer. Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480 [TBL] [Abstract][Full Text] [Related]
17. Prognostic role of serum p53 antibodies in lung cancer. Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692 [TBL] [Abstract][Full Text] [Related]
18. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306 [TBL] [Abstract][Full Text] [Related]
19. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839 [TBL] [Abstract][Full Text] [Related]